[go: up one dir, main page]

MX2009013196A - Profarmacos mutuos y metodos para tratar el cancer. - Google Patents

Profarmacos mutuos y metodos para tratar el cancer.

Info

Publication number
MX2009013196A
MX2009013196A MX2009013196A MX2009013196A MX2009013196A MX 2009013196 A MX2009013196 A MX 2009013196A MX 2009013196 A MX2009013196 A MX 2009013196A MX 2009013196 A MX2009013196 A MX 2009013196A MX 2009013196 A MX2009013196 A MX 2009013196A
Authority
MX
Mexico
Prior art keywords
methods
mutual prodrugs
mutual
retinoic acid
prodrugs
Prior art date
Application number
MX2009013196A
Other languages
English (en)
Inventor
Vincent C O Njar
Lalji K Gediya
Aakanksha Khandelwal
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Publication of MX2009013196A publication Critical patent/MX2009013196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/66—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Profármacos mutuos que comprenden retinoides e inhibidores de histon deacetilasa, métodos para la producción de los profármacos mutuos, y métodos de tratamiento que comprenden la administración de los profármacos mutuos. Los retinoides incluyen ácido retinoico todo trans, ácido 13-cis-retinólco, y análogos de ácido retinoico que tienen una sustitución en C-4. Además, los profármacos mutuos de la presente invención pueden ser utilizados como agentes terapéuticos para el tratamiento de cáncer y enfermedades y condiciones dermatológicas. Las composiciones farmacéuticas que comprenden los profármacos mutuos.
MX2009013196A 2007-06-06 2008-06-06 Profarmacos mutuos y metodos para tratar el cancer. MX2009013196A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92493207P 2007-06-06 2007-06-06
US92499507P 2007-06-07 2007-06-07
PCT/US2008/066103 WO2008154372A1 (en) 2007-06-06 2008-06-06 Mutual prodrugs and methods to treat cancer

Publications (1)

Publication Number Publication Date
MX2009013196A true MX2009013196A (es) 2010-03-30

Family

ID=40130145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013196A MX2009013196A (es) 2007-06-06 2008-06-06 Profarmacos mutuos y metodos para tratar el cancer.

Country Status (5)

Country Link
US (1) US20100184812A1 (es)
EP (1) EP2164480A1 (es)
CA (1) CA2690265A1 (es)
MX (1) MX2009013196A (es)
WO (1) WO2008154372A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
ITMI20130995A1 (it) * 2013-06-17 2014-12-18 Chemelectiva S R L Derivati dell'acido retinoico e processo per la loro preparazione

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EP1305274A4 (en) * 2000-07-11 2005-10-12 Univ Maryland NEW RETINOIDS SUBSTITUTED IN C-4
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
KR20130050395A (ko) * 2004-03-26 2013-05-15 디에스엠 아이피 어셋츠 비.브이. 히스톤 데아세틸라제(ｈｄａｃ) 저해제를 레티노이드와 함께 포함하는 조성물
WO2008154402A2 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer

Also Published As

Publication number Publication date
CA2690265A1 (en) 2008-12-18
WO2008154372A1 (en) 2008-12-18
US20100184812A1 (en) 2010-07-22
EP2164480A1 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
IL203448A (en) History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them
MX2018001487A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6 y la composición farmacéutica que comprende los mismos.
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX384527B (es) Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
IL188172A0 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
PH12015502425A1 (en) Novel compounds for selective histone deacetylase inhibitors, and pharmeceutical composition comprising the same
JP2013523708A5 (es)
UA104320C2 (ru) Фармацевтическая композиция на основе митохондриально-адресованного антиоксиданта для применения в медицинской и ветеринарной офтальмологии
MY165117A (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12020550788A1 (en) Compositions and methods for the treatment of metabolic conditions
EP2558102A4 (en) SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
PH12012501389A1 (en) Hedgehog inhibitors
MX2015016497A (es) Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
WO2010075287A3 (en) Compounds and methods for the treatment of pain and other diseases
MX2009013196A (es) Profarmacos mutuos y metodos para tratar el cancer.
MX2015000488A (es) Derivados de cromanil para tratar enfermedad mitocondrial.